{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T17:36:21Z","timestamp":1792431381698,"version":"4.5.0"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T00:00:00Z","timestamp":1766707200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T00:00:00Z","timestamp":1766707200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-025-03214-1","type":"journal-article","created":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T10:15:20Z","timestamp":1766744120000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Revisiting the use of steroids in oncology"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6245-9739","authenticated-orcid":false,"given":"Sai","family":"Prasath","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0796-4502","authenticated-orcid":false,"given":"S. P.","family":"Harsha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9380-5144","authenticated-orcid":false,"given":"Anusha Mruthyunjaya","family":"Swamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-7821-2058","authenticated-orcid":false,"given":"Karthik","family":"Jayalingappa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7764-0044","authenticated-orcid":false,"given":"Mayank","family":"Kapoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6378-7694","authenticated-orcid":false,"given":"Deepak","family":"Sundriyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7100-8999","authenticated-orcid":false,"given":"Amit","family":"Sehrawat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7762-803X","authenticated-orcid":false,"given":"Uttam Kumar","family":"Nath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,26]]},"reference":[{"key":"3214_CR1","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1084\/jem.93.1.37","volume":"93","author":"M BJ\u00d8RNEBOE","year":"1951","unstructured":"Bj\u00f8rneboe M, Fischel EE, Stoerk HC. The effect of cortisone and adrenocorticotrophic hormone on the concentration of circulating antibody. J Exp Med. 1951;93:37\u201348.","journal-title":"J Exp Med"},{"key":"3214_CR2","doi-asserted-by":"publisher","first-page":"1758004","DOI":"10.1080\/2162402X.2020.1758004","volume":"9","author":"M Vormehr","year":"2020","unstructured":"Vormehr M, Lehar S, Kranz LM, Tahtinen S, Oei Y, Javinal V, et al. Dexamethasone premedication suppresses vaccine-induced immune responses against cancer. Oncoimmunology. 2020;9:1758004.","journal-title":"Oncoimmunology"},{"key":"3214_CR3","first-page":"1","volume":"8","author":"IB Mitre-Aguilar","year":"2015","unstructured":"Mitre-Aguilar IB, Cabrera-Quintero AJ, Zentella-Dehesa A. Genomic and non-genomic effects of glucocorticoids: implications for breast cancer. Int J Clin Exp Pathol. 2015;8:1.","journal-title":"Int J Clin Exp Pathol"},{"key":"3214_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2022.103826","author":"A Faggiano","year":"2022","unstructured":"Faggiano A, Mazzilli R, Natalicchio A, Adinolfi V, Argentiero A, Danesi R, et al. Corticosteroids in oncology: use, overuse, indications, contraindications. An Italian Association of Medical Oncology (AIOM)\/ Italian Association of Medical Diabetologists (AMD)\/ Italian Society of Endocrinology (SIE)\/ Italian Society of Pharmacology (SIF) multidisciplinary consensus position paper. Crit Rev Oncol Hematol. 2022. https:\/\/doi.org\/10.1016\/j.critrevonc.2022.103826.","journal-title":"Crit Rev Oncol Hematol"},{"key":"3214_CR5","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.prro.2022.07.003","volume":"13","author":"KN Kim","year":"2023","unstructured":"Kim KN, LaRiviere M, Macduffie E, White CA, Jordan-Luft MM, Anderson E, et al. Use of glucocorticoids in patients with cancer: potential benefits, harms, and practical considerations for clinical practice. Pract Radiat Oncol. 2023;13:28\u201340.","journal-title":"Pract Radiat Oncol"},{"key":"3214_CR6","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.tips.2018.11.002","volume":"40","author":"RA Panettieri","year":"2019","unstructured":"Panettieri RA, Schaafsma D, Amrani Y, Koziol-White C, Ostrom R, Tliba O. Non-genomic effects of glucocorticoids: an updated view. Trends Pharmacol Sci. 2019;40:38\u201349.","journal-title":"Trends Pharmacol Sci"},{"issue":"6","key":"3214_CR7","first-page":"1681","volume":"8","author":"S Greenstein","year":"2002","unstructured":"Greenstein S, Ghias K, Krett NL, Rosen ST. Mechanisms of glucocorticoid-mediated apoptosis in hematological malignancies. Clin Cancer Res. 2002;8(6):1681\u201394.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"3214_CR8","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.ccell.2024.04.007","volume":"42","author":"J Choi","year":"2024","unstructured":"Choi J, Ceribelli M, Phelan JD, H\u00e4upl B, Huang DW, Wright GW, et al. Molecular targets of glucocorticoids that elucidate their therapeutic efficacy in aggressive lymphomas. Cancer Cell. 2024;42(5):833\u2013e84912.","journal-title":"Cancer Cell"},{"key":"3214_CR9","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1182\/blood.V58.6.1198.1198","volume":"58","author":"G Shipman","year":"1981","unstructured":"Shipman G, Bloomfield C, Smith K, Peterson B, Munck A. The effects of glucocorticoid therapy on glucocorticoid receptors in leukemia and lymphoma. Blood. 1981;58:1198\u2013202.","journal-title":"Blood"},{"key":"3214_CR10","doi-asserted-by":"publisher","first-page":"475","DOI":"10.3324\/haematol.11903","volume":"93","author":"M Dungarwalla","year":"2008","unstructured":"Dungarwalla M, Evans SO, Riley U, Catovsky D, Dearden CE, Matutes E. High dose methylprednisolone and rituximab is an effective therapy in advanced refractory chronic lymphocytic leukemia resistant to fludarabine therapy. Haematologic. 2008;93:475\u20136.","journal-title":"Haematologic"},{"key":"3214_CR11","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1182\/blood-2007-11-124156","volume":"112","author":"S Sharma","year":"2008","unstructured":"Sharma S, Liechtenstein A. Dexamethasone-induced apoptotic mechanisms in myeloma cells investigated by analysis of mutant glucocorticoid receptors. Blood. 2008;112:1338\u201345.","journal-title":"Blood"},{"key":"3214_CR12","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s00277-018-3465-8","volume":"98","author":"N Burwick","year":"2019","unstructured":"Burwick N, Sharma S. Glucocorticoids in multiple myeloma: past, present, and future. Ann Hematol. 2019;98:19\u201328.","journal-title":"Ann Hematol"},{"issue":"3","key":"3214_CR13","first-page":"647","volume":"2","author":"B Scheijen","year":"2019","unstructured":"Scheijen B. Molecular mechanisms contributing to glucocorticoid resistance in lymphoid malignancies. Cancer Drug Resist. 2019;2(3):647\u201364.","journal-title":"Cancer Drug Resist"},{"key":"3214_CR14","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1007\/s11940-010-0066-9","volume":"12","author":"JE Greenlee","year":"2010","unstructured":"Greenlee JE. Treatment of paraneoplastic neurologic disorders. Curr Treat Options Neuro. 2010;12:212\u201330.","journal-title":"Curr Treat Options Neuro"},{"key":"3214_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1551111","volume":"16","author":"P Martinez","year":"2025","unstructured":"Martinez P, Sabatier JM. Rethinking corticosteroids use in oncology. Frontiers in Pharmacology. 2025;16:1551111.","journal-title":"Frontiers in Pharmacology"},{"issue":"4","key":"3214_CR16","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1056\/NEJMoa011795","volume":"346","author":"B Coiffier","year":"2002","unstructured":"Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(4):235\u201342. https:\/\/doi.org\/10.1056\/NEJMoa011795.","journal-title":"N Engl J Med"},{"key":"3214_CR17","doi-asserted-by":"publisher","first-page":"2773","DOI":"10.1182\/BLOOD-2006-07-036673","volume":"109","author":"C Patte","year":"2007","unstructured":"Patte C, Auperin A, Gerrard M, Michon J, Pinkerton R, Sposto R, et al. Results of the randomized international FAB\/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients. Blood. 2007;109:2773\u201380. https:\/\/doi.org\/10.1182\/BLOOD-2006-07-036673.","journal-title":"Blood"},{"key":"3214_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(16)00036-3","volume":"3","author":"AJM Ferreri","year":"2016","unstructured":"Ferreri AJM, Cwynarski K, Pulczynski E, Ponzoni M, Deckert M, Politi LS, et al. Chemo-immunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. Lancet Haematol. 2016;3:e217. https:\/\/doi.org\/10.1016\/S2352-3026(16)00036-3.","journal-title":"Lancet Haematol"},{"key":"3214_CR19","doi-asserted-by":"publisher","first-page":"2687","DOI":"10.1182\/BLOOD-2008-03-147025","volume":"112","author":"CH Geisler","year":"2008","unstructured":"Geisler CH, Kolstad A, Laurell A, Andersen NS, Pedersen LB, Jerkeman M, et al. Long-term progression-free survival of mantle cell lymphoma after intensive frontline immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood. 2008;112:2687\u201393. https:\/\/doi.org\/10.1182\/BLOOD-2008-03-147025.","journal-title":"Blood"},{"key":"3214_CR20","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1182\/BLOOD-2004-08-3175","volume":"105","author":"R Marcus","year":"2005","unstructured":"Marcus R, Imrie K, Belch A, Cunningham D, Flores E, Catalano J, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood. 2005;105:1417\u201323. https:\/\/doi.org\/10.1182\/BLOOD-2004-08-3175.","journal-title":"Blood"},{"key":"3214_CR21","doi-asserted-by":"publisher","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","volume":"26","author":"JM Vose","year":"2008","unstructured":"Vose JM, Neumann M, Harris ME. International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes international T-cell lymphoma project. J Clin Oncol. 2008;26:4124\u201330. https:\/\/doi.org\/10.1200\/JCO.2008.16.4558.","journal-title":"J Clin Oncol"},{"key":"3214_CR22","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1182\/BLOOD.V94.4.1209","volume":"94","author":"M D\u00f6rdelmann","year":"1999","unstructured":"D\u00f6rdelmann M, Reiter A, Borkhardt A, Ludwig W-D, G\u00f6tz N, Viehmann S, et al. Prednisone response is the strongest predictor of treatment outcome in infant acute lymphoblastic leukemia. Blood. 1999;94:1209\u201317. https:\/\/doi.org\/10.1182\/BLOOD.V94.4.1209.","journal-title":"Blood"},{"key":"3214_CR23","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1182\/blood-2008-04-150250","volume":"113","author":"MA Sanz","year":"2009","unstructured":"Sanz MA, Grimwade D, Tallman MS, Lowenberg B, Fenaux P, Estey EH, et al. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2009;113:1875\u201391.","journal-title":"Blood"},{"key":"3214_CR24","doi-asserted-by":"publisher","first-page":"3205","DOI":"10.1182\/blood-2011-06-297853","volume":"118","author":"SV Rajkumar","year":"2011","unstructured":"Rajkumar SV, Gahrton G, Bergsagel PL. Approach to the treatment of multiple myeloma: a clash of philosophies. Blood. 2011;118:3205\u201311.","journal-title":"Blood"},{"key":"3214_CR25","doi-asserted-by":"publisher","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","volume":"111","author":"M Hallek","year":"2008","unstructured":"Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, D\u00f6hner H, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the international workshop on chronic lymphocytic leukemia updating the National cancer Institute-Working group 1996 guidelines. Blood. 2008;111:5446\u201356.","journal-title":"Blood"},{"key":"3214_CR26","doi-asserted-by":"publisher","first-page":"3601","DOI":"10.1200\/JCO.2003.03.023","volume":"21","author":"A Engert","year":"2003","unstructured":"Engert A, Schiller P, Josting A, Herrmann R, Koch P, Sieber M, et al. Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin\u2019s lymphoma: results of the HD8 trial of the German Hodgkin\u2019s lymphoma study group. J Clin Oncol. 2003;21:3601\u20138.","journal-title":"J Clin Oncol"},{"issue":"5","key":"3214_CR27","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S1470-2045(06)70694-5","volume":"7","author":"I Herr","year":"2006","unstructured":"Herr I, Pfitzenmaier J. Glucocorticoid use in prostate cancer and other solid tumours: implications for effectiveness of cytotoxic treatment and metastases. Lancet Oncol. 2006;7(5):425\u201330. https:\/\/doi.org\/10.1016\/S1470-2045(06)70694-5.","journal-title":"Lancet Oncol"},{"key":"3214_CR28","doi-asserted-by":"publisher","DOI":"10.1177\/1178223420974667","volume":"14","author":"EM Zhidkova","year":"2020","unstructured":"Zhidkova EM, Lylova ES, Savinkova AV, Mertsalov SA, Kirsanov KI, Belitsky GA, et al. A brief overview of the paradoxical role of glucocorticoids in breast cancer. Breast Cancer (Auckl). 2020;14:1178223420974667. https:\/\/doi.org\/10.1177\/1178223420974667.","journal-title":"Breast Cancer (Auckl)"},{"key":"3214_CR29","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1093\/nop\/npu029","volume":"2","author":"P Roth","year":"2015","unstructured":"Roth P, Happold C, Weller M. Corticosteroid use in neuro-oncology: an update. Neurooncol Pract. 2015;2:6\u201312. https:\/\/doi.org\/10.1093\/nop\/npu029.","journal-title":"Neurooncol Pract"},{"key":"3214_CR30","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1515\/jtim-2016-0010","volume":"4","author":"F Ryckeghem","year":"2016","unstructured":"Van Ryckeghem F. Corticosteroids, the oldest agent in the prevention of chemotherapy-induced nausea and vomiting: what about the guidelines? J Transl Intern Med. 2016;4:46.","journal-title":"J Transl Intern Med"},{"issue":"24","key":"3214_CR31","doi-asserted-by":"publisher","first-page":"2782","DOI":"10.1200\/JCO.20.01296","volume":"38","author":"PJ Hesketh","year":"2020","unstructured":"Hesketh PJ, Kris MG, Basch E, Bohlke K, Barbour SY, Clark-Snow RA, et al. Antiemetics: ASCO guideline update. J Clin Oncol. 2020;38(24):2782\u201397.","journal-title":"J Clin Oncol"},{"issue":"suppl4","key":"3214_CR32","doi-asserted-by":"publisher","first-page":"iv84","DOI":"10.1093\/annonc\/mdx221","volume":"28","author":"E Le Rhun","year":"2017","unstructured":"Le Rhun E, Weller M, Brandsma D, Van den Bent M, de Azambuja E, Henriksson R, et al. EANO executive board and ESMO guidelines Committee. EANO-ESMO clinical practice guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours. Ann Oncol. 2017;28(suppl4):iv84\u201399.","journal-title":"Ann Oncol"},{"key":"3214_CR33","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1177\/2192568217699189","volume":"7","author":"GD Skeoch","year":"2017","unstructured":"Skeoch GD, Tobin MK, Khan S, Linninger AA, Mehta AI. Corticosteroid treatment for metastatic spinal cord compression: a review. Glob Spine J. 2017;7:272.","journal-title":"Glob Spine J"},{"key":"3214_CR34","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1093\/neuonc\/noad169","volume":"25","author":"B Nabors","year":"2023","unstructured":"Nabors B, Portnow J, Hattangadi-Gluth J, Horbinski C. NCCN CNS tumor guidelines update for 2023. Neuro Oncol. 2023;25:2114.","journal-title":"Neuro Oncol"},{"issue":"2","key":"3214_CR35","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.annonc.2020.11.003","volume":"32","author":"P Roth","year":"2021","unstructured":"Roth P, Pace A, Le Rhun E, Weller M, Ay C, Cohen-Jonathan Moyal E, et al. EANO executive Board. Electronic address: office@eano.eu; ESMO guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Neurological and vascular complications of primary and secondary brain tumours: EANO-ESMO clinical practice guidelines for prophylaxis, diagnosis, treatment and follow-up. Ann Oncol. 2021;32(2):171\u201382.","journal-title":"Ann Oncol"},{"key":"3214_CR36","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1053\/clon.2002.0095","volume":"14","author":"NP Rowell","year":"2002","unstructured":"Rowell NP, Gleeson FV. Steroids, radiotherapy, chemotherapy and stents for superior vena caval obstruction in carcinoma of the bronchus: a systematic review. Clin Oncol. 2002;14:338\u201351.","journal-title":"Clin Oncol"},{"key":"3214_CR37","first-page":"e20924","volume":"14","author":"V Patriarcheas","year":"2022","unstructured":"Patriarcheas V, Grammoustianou M, Ptohis N, Thanou I, Kostis M, Gkiozos I, et al. Malignant Superior Vena Cava Syndrome: State Art Cureus. 2022;14:e20924.","journal-title":"Malignant Superior Vena Cava Syndrome: State Art Cureus"},{"key":"3214_CR38","unstructured":"Anastasopoulou C, Mewawalla P. Malignancy-Related Hypercalcemia. StatPearls. 2025."},{"issue":"2","key":"3214_CR39","doi-asserted-by":"publisher","first-page":"269","DOI":"10.7326\/0003-4819-93-2-269","volume":"93","author":"ML Binstock","year":"1980","unstructured":"Binstock ML, Mundy GR. Effect of calcitonin and glucocorticoids in combination on the hypercalcemia of malignancy. Ann Intern Med. 1980;93(2):269\u201372.","journal-title":"Ann Intern Med"},{"issue":"21","key":"3214_CR40","doi-asserted-by":"publisher","first-page":"2438","DOI":"10.1200\/JCO.20.00611","volume":"38","author":"EJ Roeland","year":"2020","unstructured":"Roeland EJ, Bohlke K, Baracos VE, Bruera E, Del Fabbro E, Dixon S, et al. Management of cancer cachexia: ASCO guideline. J Clin Oncol. 2020;38(21):2438\u201353.","journal-title":"J Clin Oncol"},{"key":"3214_CR41","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1196\/annals.1321.010","volume":"1024","author":"IJ Elenkov","year":"2004","unstructured":"Elenkov IJ. Glucocorticoids and the Th1\/Th2 balance. Ann N Y Acad Sci. 2004;1024:138\u201346.","journal-title":"Ann N Y Acad Sci"},{"key":"3214_CR42","doi-asserted-by":"publisher","first-page":"3583","DOI":"10.1200\/JCO.21.01200","volume":"39","author":"OM Lansinger","year":"2021","unstructured":"Lansinger OM, Biedermann S, He Z, Dimitrios Colevas A. Do steroids matter? A retrospective review of premedication for taxane chemotherapy and hypersensitivity reactions. J Clin Oncol. 2021;39:3583\u201390.","journal-title":"J Clin Oncol"},{"key":"3214_CR43","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s11864-023-01170-4","volume":"25","author":"EA Karlsen","year":"2024","unstructured":"Karlsen EA, Walpole E, Simpson F. Steroid premedication and monoclonal antibody therapy: should we reconsider? Curr Treat Options Oncol. 2024;25:275\u201383.","journal-title":"Curr Treat Options Oncol"},{"key":"3214_CR44","first-page":"810","volume":"12","author":"PD Clemmons","year":"2021","unstructured":"Clemmons PD, Gandhi BCOPA, PharmD BCOPA, Clarke PDA, Jimenez APN-BC, Le AGACNPAOCNPS, Ajebo MDT. Premedications for cancer therapies: A primer for the Hematology\/Oncology provider. J Adv Pract Oncol. 2021;12:810.","journal-title":"J Adv Pract Oncol"},{"key":"3214_CR45","doi-asserted-by":"publisher","first-page":"e232","DOI":"10.3346\/jkms.2022.37.e232","volume":"37","author":"JH Kim","year":"2022","unstructured":"Kim JH. Time to care for adrenal insufficiency in cancer patients. J Korean Med Sci. 2022;37:e232.","journal-title":"J Korean Med Sci"},{"key":"3214_CR46","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.836859","volume":"12","author":"S Jessel","year":"2022","unstructured":"Jessel S, Weiss SA, Austin M, Mahajan A, Etts K, Zhang L, et al. Immune Checkpoint Inhibitor-Induced Hypophysitis and Patterns of Loss of Pituitary Function. Front Oncol. 2022;12:836859.","journal-title":"Front Oncol"},{"key":"3214_CR47","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/b978-0-12-823912-4.00015-3","volume":"200","author":"J Kerstens","year":"2024","unstructured":"Kerstens J, Titulaer MJ. Overview of treatment strategies in paraneoplastic neurological syndromes. Handb Clin Neurol. 2024;200:97\u2013112. https:\/\/doi.org\/10.1016\/b978-0-12-823912-4.00015-3.","journal-title":"Handb Clin Neurol"},{"key":"3214_CR48","doi-asserted-by":"publisher","DOI":"10.3390\/cells11050770","author":"L Kalfeist","year":"2022","unstructured":"Kalfeist L, Galland L, Ledys F, Ghiringhelli F, Limagne E, Ladoire S. Impact of glucocorticoid use in oncology in the immunotherapy era. Cells. 2022. https:\/\/doi.org\/10.3390\/cells11050770.","journal-title":"Cells"},{"key":"3214_CR49","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.3389\/fimmu.2019.01744","volume":"10","author":"C Strehl","year":"2019","unstructured":"Strehl C, Ehlers L, Gaber T, Buttgereit F. Glucocorticoids-all-rounders tackling the versatile players of the immune system. Front Immunol. 2019;10:1744.","journal-title":"Front Immunol"},{"key":"3214_CR50","doi-asserted-by":"publisher","first-page":"770","DOI":"10.3390\/cells11050770","volume":"11","author":"L Kalfeist","year":"2022","unstructured":"Kalfeist L, Galland L, Ledys F, Ghiringhelli F, Limagne E, Ladoire S. Impact of glucocorticoid use in oncology in the immunotherapy era. Cells. 2022;11:770.","journal-title":"Cells"},{"issue":"1","key":"3214_CR51","doi-asserted-by":"publisher","first-page":"1758004","DOI":"10.1080\/2162402X.2020.1758004","volume":"9","author":"M Vormehr","year":"2020","unstructured":"Vormehr M, Lehar S, Kranz LM, Tahtinen S, Oei Y, Javinal V, et al. Dexamethasone premedication suppresses vaccine-induced immune responses against cancer. Oncoimmunology. 2020;9(1):1758004.","journal-title":"Oncoimmunology"},{"key":"3214_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2022.103826","author":"A Faggiano","year":"2022","unstructured":"Faggiano A, Mazzilli R, Natalicchio A, Adinolfi V, Argentiero A, Danesi R, et al. Corticosteroids in oncology: use, overuse, indications, contraindications. An Italian Association of Medical Oncology (AIOM)\/ Italian Association of Medical Diabetologists (AMD)\/ Italian Society of Endocrinology (SIE)\/ Italian Society of Pharmacology (SIF) multidisciplinary consensus position paper. Crit Rev Oncol Hematol. 2022. https:\/\/doi.org\/10.1016\/j.critrevonc.2022.103826.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"14","key":"3214_CR53","doi-asserted-by":"publisher","first-page":"2580","DOI":"10.1158\/1078-0432.CCR-22-3181","volume":"29","author":"RS Goodman","year":"2023","unstructured":"Goodman RS, Johnson DB, Balko JM. Corticosteroids and cancer immunotherapy. Clin Cancer Res. 2023;29(14):2580\u20137.","journal-title":"Clin Cancer Res"},{"key":"3214_CR54","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16101892","volume":"16","author":"S Syed","year":"2024","unstructured":"Syed S, Hines J, Baccile R, Rouhani S, Reid P. Studying outcomes after steroid-sparing immunosuppressive agent vs. steroid-only treatment for immune-related adverse events in Non-Small-Cell Lung Cancer (NSCLC) and melanoma: a retrospective case-control study. Cancers (Basel). 2024;16:1892.","journal-title":"Cancers (Basel)"},{"key":"3214_CR55","doi-asserted-by":"publisher","first-page":"100713","DOI":"10.1016\/j.iotech.2024.100713","volume":"22","author":"F Costa Svedman","year":"2024","unstructured":"Costa Svedman F, Liapi M, M\u00e5nsson-Broberg A, Chatzidionysiou K, Egyhazi Brage S. Effect of glucocorticoids for the management of immune-related adverse events on outcome in melanoma patients treated with immunotherapy-a retrospective and biomarker study. Immunooncol Technol. 2024;22:100713.","journal-title":"Immunooncol Technol"},{"key":"3214_CR56","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx225","volume":"28","author":"JBAG Haanen","year":"2017","unstructured":"Haanen JBAG, Carbonnel F, Robert C, Kerr KM, Peters S, Larkin J, et al. Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28:iv119\u201342.","journal-title":"Ann Oncol"},{"issue":"20","key":"3214_CR57","doi-asserted-by":"publisher","first-page":"2430","DOI":"10.1182\/blood.2022017414","volume":"141","author":"MD Jain","year":"2023","unstructured":"Jain MD, Smith M, Shah NN. How i treat refractory CRS and ICANS after CAR T-cell therapy. Blood. 2023;141(20):2430\u201342. https:\/\/doi.org\/10.1182\/blood.2022017414.","journal-title":"Blood"},{"key":"3214_CR58","first-page":"707","volume":"4","author":"L Rowbottom","year":"2015","unstructured":"Rowbottom L, Stinson J, McDonald R, Emmenegger U, Cheng S, Lowe J, et al. Retrospective review of the incidence of monitoring blood glucose levels in patients receiving corticosteroids with systemic anticancer therapy. Ann Palliat Med. 2015;4:707\u201377.","journal-title":"Ann Palliat Med"},{"key":"3214_CR59","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/S11914-019-00536-8","volume":"17","author":"AM El Badri","year":"2019","unstructured":"El Badri AM, Salawu S, Brown A. Bone health in men with prostate cancer: review article. Curr Osteoporos Rep. 2019;17:527\u201337. https:\/\/doi.org\/10.1007\/S11914-019-00536-8.","journal-title":"Curr Osteoporos Rep"},{"key":"3214_CR60","doi-asserted-by":"publisher","DOI":"10.1002\/pon.70137","volume":"34","author":"N Seymour","year":"2025","unstructured":"Seymour N, Ismail MF, Doherty K, Bowler A, Bambury R, Iqbal S, et al. Steroid-induced mental disorders in oncology patients: a 10\u2010year retrospective case series review. Psychooncology. 2025;34:e70137.","journal-title":"Psychooncology"},{"key":"3214_CR61","doi-asserted-by":"publisher","first-page":"e004587","DOI":"10.1136\/bmjopen-2013-004587","volume":"4","author":"S Narum","year":"2014","unstructured":"Narum S, Westergren T, Klemp M. Corticosteroids and risk of gastrointestinal bleeding: a systematic review and meta-analysis. BMJ Open. 2014;4:e004587.","journal-title":"BMJ Open"},{"key":"3214_CR62","doi-asserted-by":"publisher","DOI":"10.3390\/JPM12111829","volume":"12","author":"C Kelley","year":"2022","unstructured":"Kelley C, Vander Molen J, Choi J, Bhai S, Martin K, Cochran C, et al. Impact of glucocorticoids on cardiovascular system\u2014the Yin Yang effect. J Pers Med. 2022;12:1829. https:\/\/doi.org\/10.3390\/JPM12111829.","journal-title":"J Pers Med"},{"issue":"4","key":"3214_CR63","doi-asserted-by":"publisher","DOI":"10.1128\/microbiolspec.DMIH2-0026-2016","volume":"4","author":"LK Dropulic","year":"2016","unstructured":"Dropulic LK, Lederman HM. Overview of infections in the immunocompromised host. Microbiol Spectr. 2016;4(4):10.1128\/microbiolspec.DMIH2-0026-2016.","journal-title":"Microbiol Spectr"},{"key":"3214_CR64","first-page":"109","volume":"99","author":"M Asencio-Dur\u00e1n","year":"2024","unstructured":"Asencio-Dur\u00e1n M, Fern\u00e1ndez-Guti\u00e9rrez E, Larra\u00f1aga-Cores M, Klein-Burgos C, Dabad-Moreno JV, Capote-D\u00edez M. Ocular side effects of oncological therapies: review. Arch De La Sociedad Espa\u00f1ola De Oftalmolog\u00eda (English Edition). 2024;99:109\u201332.","journal-title":"Arch De La Sociedad Espa\u00f1ola De Oftalmolog\u00eda (English Edition)"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-03214-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-025-03214-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-03214-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T16:04:01Z","timestamp":1770393841000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-025-03214-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,26]]},"references-count":64,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["3214"],"URL":"https:\/\/doi.org\/10.1007\/s12032-025-03214-1","relation":{},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,26]]},"assertion":[{"value":"22 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"97"}}